top of page
Biomind Labs - Next-gen pharma
Reaching a new summit for the medical treatment of neurological disorders

Next-Gen Pharma

Next-Gen

Pharma

Biomind Labs is developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders. 

We focus our research in transforming biomedical sciences knowledge into fast-acting and controlled-release novel drugs.
Our tailored drug delivery systems targets specific therapeutic indications that go beyond mental health conditions.
Biomind Labs is developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders. 

This unique approach targets the original and initial drivers of the diseases.
R&D to change lives

R&D to

change

lives.

​Biomind Labs' commitment is to provide patients and the psychiatric community with novel pharmaceuticals that provide a comfortable, safe and efficient use.
Our commitment is to provide patients and the psychiatric community with novel pharmaceuticals that provide a comfortable, safe and efficient use.
Reaching a new summit for the medical treatment of neurological disorders.

Following strict scientific standards to protect patients and help produce reliable clinical trials results

Treatment-Resistant Depression

BMND01
LEARN MORE
PHASE II

Fibromyalgia

BMND02
LEARN MORE
EVALUATION

Addictive Disorders

BMND03
LEARN MORE
PRE-CLINICAL

Chronic Pain

BMND05
LEARN MORE
EVALUATION

Morbid Obesity

BMND06
LEARN MORE
PHASE I

Major Depressive Disorder

BMND07
LEARN MORE
EVALUATION

Alzheimer's

BMND08
PHASE II

Parkinson's Disease

BMND09
LEARN MORE
PHASE I

19 patents applications derived from 8 priority documents PCT and EPO Written Opinions (ISR/WO): Very promising

19

  • (USPTO) United States Patent and Trademark Office
  • (PCT) Patent Cooperation Treaty
  • (EPO) European Patent Office

Across every stage of the molecule to market lifecycle.

A Robust IP Strategy

Our academic & corporate credentials

Elevating Healthcare Standards

Alejandro Antalich

Chief Executive Officer & Director

Alejandro Antalich

Oscar León

Chief Financial Officer & Director

Oscar León

Paola Díaz Dellavalle

Chief Scientific Officer

Paola Díaz Dellavalle

Juan Presa

Chief Legal Officer

Juan Presa

Martín Bruno

Clinical Advisor

Martín Bruno

Martín Daners

Head of Quality Assurance and Regulatory Affairs

Martín Daners

Lucía Minini

Scientific Laboratory Manager

Lucía Minini

Florencia Ferraro

Biomolecular Research Scientist

Florencia Ferraro

Ravi Sood

Chairman of the Board

Ravi Sood

Dr. Ben Illigens

Director

Dr. Ben Illigens

An experienced Board and Management with diverse public company experience, life sciences domain expertise form the Department of Neurology at Harvard Medical School and proven experience working with psychotropic substances in several jurisdictions and negotiating with government authorities and health agencies.

Our highly qualified team of scientists with more than fifteen years of experience in research, development, and management in life sciences projects, aim to go beyond behavioural studies and work on elucidating the biochemical and neurological mechanisms of our portfolio of molecules.

We are developing:
​An unique portfolio of molecules, aimed to offer patients access to cost-effective and cutting-edge psychiatric treatments.

01

A unique portfolio of molecules, aimed to offer patients access to cost-effective and cutting-edge psychiatric treatments.
​The most diversified pipeline of clinical trials targeting multiple diseases to seek fast-track approvals and breakthrough therapy designations for novel pharmaceuticals.

02

The most diversified pipeline of clinical trials targeting multiple diseases to seek fast-track approvals and breakthrough therapy designations for novel pharmaceuticals.

03

Complex products, on-demand products, and customised products, controlling the time and place of drug release for the specific needs of each patient.

04

A personalized medicine and a sustainable production to provide a democratic access to our novel pharmaceuticals regardless the income level of patients.
​Complex products, on-demand products, and customised products, controlling the time and place of drug release for the specific needs of each patient.
​A personalized medicine and a sustainable production to provide a democratic access to our novel pharmaceuticals regardless the income level of patients.

Newsroom

Biomind Labs to redefine Obesity Treatment with its new BMND06 candidate targeting neurological pathways

July 19, 2024

Biomind Labs Announces Unprecedented Positive Results of Phase 2 Clinical Trial of BMND08 for Depression & Anxiety in Alzheimer’s Disease

March 1, 2024

Biomind Labs Provides Corporate Update

September 27, 2023

Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications

September 14, 2023

Biomind Labs Announces the Start of the First-Ever Clinical Trial Targeting Depression & Anxiety in Alzheimer’s Disease With Its BMND08 Candidate

April 25, 2023

Investors. Biomind Labs
Investors. Biomind Labs

Commitment to transparency with our patients, the medical community, and our investors. Trust, clarity and innovation are the pillars that accompany us in every step we take.

Investors

Investors. Biomind Labs
bottom of page